Ticagrelor vs. Clopidogrel in Post PCI Patients
CompletedNot applicableNCT05858918
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Elective PCI were included in the study. Patients were randomized into two different groups. One group took ASA 80 mg once daily and clopidogrel 75 mg once a day, and the other one took ASA 80 mg once a day and ticagrelor 90 mg twice a day. After six months of close follow-up, patients were asked to give a score to their dyspnea and asked about the major advance cardiovascular events ( MACE)
Study details
- Official title
- Evaluation the Effect of Ticagrelor and Clopidogrel in Stable Coronary Syndrome A Randomized Clinical Trial
- Conditions
- Interventions
- Drug: Clopidogrel
- Drug: Ticagrelor
- Sponsor
- Shiraz University of Medical Sciences
- Start date
- 2022-10-01
- Primary completion
- 2023-03-01
- Sex
- All
- Age range
- from 50 Years to 76 Years
- Results posted
- No results posted in this snapshot
- Countries
- Iran
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Experiencing elective percutaneous coronary intervention (PCI). Exclusion Criteria: * Patients diagnosed with hypersensitivity to either ticagrelor or clopidogrel * Active pathological bleeding * Patients who consumed anticoagulants in the course of their medical therapy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05858918